# AceCann

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acecann

- Industry: Pharmaceuticals
- Headquarters: Portugal
- Website: www.acecann.com/
- Total disclosed funding: $15M
- Latest round: Seed (Oct 12, 2021)
- Investors on record: 2

## About

AceCann is a Portugal-based company focused on producing high-quality medical cannabis products designed to enhance patient health and well-being.Founded in 2019, AceCann specializes in the cultivation and distribution of medical cannabis. The company has not undergone any significant business pivots or structural changes since its inception. The headquarters is located in Vendas Novas, Portugal. Founders Frederico De Brito E Abreu and Pedro Trinité have previously engaged in various ventures, contributing to their expertise in the sector. In October 2021, AceCann raised USD 15.000 mn in Seed funding led by Casa Verde Capital, with Lince Capital also participating, bringing the total amount raised to USD 15.000 mn.AceCann specializes in providing high-quality cannabis products aimed at improving patient health. Their core offerings include a range of medical cannabis strains and related products formulated for various therapeutic uses, such as pain relief, anxiety reduction, and treatment of chronic illnesses. The company focuses on cultivating cannabis with stringent quality controls, ensuring that their products meet both safety and efficacy standards for their users. AceCann serves a diverse client base, including healthcare professionals, pharmacies, and directly to patients who require medical cannabis in regions where it is legally prescribed. The primary geographical markets for AceCann's products extend across Europe, particularly in countries with established medical cannabis programs.AceCann generates revenue through a direct sales model, engaging with healthcare providers and pharmacies to distribute their medical cannabis products. The company operates with a transactional structure that supports B2B relationships, where products are sold in bulk to licensed distributors and clinics. Pricing plans are structured based on product type and volume purchased, aligning with industry standards for medical cannabis. AceCann's flagship products are strategically positioned to meet the needs of patients seeking effective treatment options, further emphasizing their commitment to quality and patient outcomes. This approach enables AceCann to maintain sustainable revenue streams while fostering long-term partnerships within the healthcare sector.In October 2021, AceCann raised USD 15.000 mn in Seed funding to develop a production facility located in Vendas Novas, Portugal, dedicated to the organic cultivation, processing, and extraction of premium medical cannabis products. The company plans to expand into additional European markets with established medical cannabis programs by 2023, leveraging the recent funding to support their growth initiatives and enhance their production capabilities.

## Funding rounds

- Seed, Oct 12, 2021, $15M — Casa Verde Capital, Lince Capital

## Investors

- Casa Verde Capital (https://capitalatlas.ai/funds/casa-verde-capital) — Seed
- Lince Capital (https://capitalatlas.ai/funds/lince-capital) — Seed